Eton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

false 0001710340 0001710340 2025-03-31 2025-03-31

 

 

 

 

 

 

 

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

On March 31, 2025, Eton Pharmaceuticals, Inc. (the “Company”) out-licensed the commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. (“Esteve”).

 

Under the terms of the agreement, Esteve will pay the Company €4 million up front to license the rights to Increlex for up to ten years, and Esteve is also receiving an option to acquire the international rights in the future for a purchase price of up to €6 million. Eton will supply product to Esteve at a fixed transfer price, and the transaction does not impact the Company’s expectation to exit 2025 at an approximately $80 million annual revenue run rate.

 

A copy of the press release announcing the transaction dated April 1, 2025 is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

 

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.